Lei Liu, Yaping Li, Shiying Tang, Bin Yang, Qiming Zhang, Ruotao Xiao, Xiaofei Hou, Cheng Liu, Lulin Ma
{"title":"Gleason评分相关的MT1L作为前列腺癌预后的生物标志物,在体外促进肿瘤进展。","authors":"Lei Liu, Yaping Li, Shiying Tang, Bin Yang, Qiming Zhang, Ruotao Xiao, Xiaofei Hou, Cheng Liu, Lulin Ma","doi":"10.1177/03936155231156458","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The Gleason Score is well correlated with biological behavior and prognosis in prostate adenocarcinoma (PRAD). This study was derived to determine the clinical significance and function of Gleason-Score-related genes in PRAD.</p><p><strong>Methods: </strong>RNA-sequencing profiles and clinical data were extracted from the The Cancer Genome Atlas PRAD database. The Gleason-Score-related genes were screened out by the Jonckheere-Terpstra rank-based test. The \"limma\" R package was performed for differentially expressed genes. Next, a Kaplan-Meier survival analysis was performed. Correlation MT1L expression levels with tumor stage, non-tumor tissue stage, radiation therapy, and residual tumor were analyzed. Further, MT1L expression was detected in PRAD cell lines by reverse transcription-quantitative polymerase chain reaction assay. Overexpression of MT1L was constructed and used for cell count kit-8, flow cytometric assay, transwell assay, and wound-healing assay.</p><p><strong>Results: </strong>Survival analysis showed 15 Gleason-Score-related genes as prognostic biomarkers in PRAD. The high-frequency deletion of MT1L was verified in PRAD. Furthermore, MT1L expression was decreased in PRAD cell lines than RWPE-1 cells, and overexpression of MT1L repressed cell proliferation and migration, and induced apoptosis in PC-3 cells.</p><p><strong>Conclusion: </strong>Gleason-Score-related MT1L may serve as a biomarker of poor prognostic biomarker in PRAD. In addition, MT1L plays a tumor suppressor in PRAD progression, which is beneficial for PRAD diagnosis and treatment research.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"38 2","pages":"114-123"},"PeriodicalIF":2.3000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Gleason Score-related MT1L as biomarker for prognosis in prostate adenocarcinoma and contribute to tumor progression in vitro.\",\"authors\":\"Lei Liu, Yaping Li, Shiying Tang, Bin Yang, Qiming Zhang, Ruotao Xiao, Xiaofei Hou, Cheng Liu, Lulin Ma\",\"doi\":\"10.1177/03936155231156458\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The Gleason Score is well correlated with biological behavior and prognosis in prostate adenocarcinoma (PRAD). This study was derived to determine the clinical significance and function of Gleason-Score-related genes in PRAD.</p><p><strong>Methods: </strong>RNA-sequencing profiles and clinical data were extracted from the The Cancer Genome Atlas PRAD database. The Gleason-Score-related genes were screened out by the Jonckheere-Terpstra rank-based test. The \\\"limma\\\" R package was performed for differentially expressed genes. Next, a Kaplan-Meier survival analysis was performed. Correlation MT1L expression levels with tumor stage, non-tumor tissue stage, radiation therapy, and residual tumor were analyzed. Further, MT1L expression was detected in PRAD cell lines by reverse transcription-quantitative polymerase chain reaction assay. Overexpression of MT1L was constructed and used for cell count kit-8, flow cytometric assay, transwell assay, and wound-healing assay.</p><p><strong>Results: </strong>Survival analysis showed 15 Gleason-Score-related genes as prognostic biomarkers in PRAD. The high-frequency deletion of MT1L was verified in PRAD. Furthermore, MT1L expression was decreased in PRAD cell lines than RWPE-1 cells, and overexpression of MT1L repressed cell proliferation and migration, and induced apoptosis in PC-3 cells.</p><p><strong>Conclusion: </strong>Gleason-Score-related MT1L may serve as a biomarker of poor prognostic biomarker in PRAD. In addition, MT1L plays a tumor suppressor in PRAD progression, which is beneficial for PRAD diagnosis and treatment research.</p>\",\"PeriodicalId\":50334,\"journal\":{\"name\":\"International Journal of Biological Markers\",\"volume\":\"38 2\",\"pages\":\"114-123\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Biological Markers\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/03936155231156458\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Biological Markers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03936155231156458","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:Gleason评分与前列腺腺癌(PRAD)的生物学行为和预后有很好的相关性。本研究旨在确定格里森评分相关基因在PRAD中的临床意义和功能。方法:从the Cancer Genome Atlas PRAD数据库中提取rna测序图谱和临床数据。gleason - score相关基因通过Jonckheere-Terpstra秩基础测试筛选出来。对差异表达基因进行“limma”R包装。接下来,进行Kaplan-Meier生存分析。分析MT1L表达水平与肿瘤分期、非肿瘤组织分期、放疗及残余肿瘤的相关性。此外,通过逆转录-定量聚合酶链反应法检测了MT1L在PRAD细胞系中的表达。构建过表达的MT1L,并将其用于细胞计数试剂盒-8、流式细胞术实验、transwell实验和伤口愈合实验。结果:生存分析显示15个gleason评分相关基因可作为PRAD的预后生物标志物。在PRAD中证实了MT1L的高频缺失。与RWPE-1细胞相比,PRAD细胞中MT1L的表达降低,MT1L的过表达抑制了PC-3细胞的增殖和迁移,诱导了细胞凋亡。结论:与gleason评分相关的MT1L可作为PRAD不良预后的生物标志物。此外,MT1L在PRAD进展中发挥抑瘤作用,有利于PRAD的诊断和治疗研究。
Gleason Score-related MT1L as biomarker for prognosis in prostate adenocarcinoma and contribute to tumor progression in vitro.
Background: The Gleason Score is well correlated with biological behavior and prognosis in prostate adenocarcinoma (PRAD). This study was derived to determine the clinical significance and function of Gleason-Score-related genes in PRAD.
Methods: RNA-sequencing profiles and clinical data were extracted from the The Cancer Genome Atlas PRAD database. The Gleason-Score-related genes were screened out by the Jonckheere-Terpstra rank-based test. The "limma" R package was performed for differentially expressed genes. Next, a Kaplan-Meier survival analysis was performed. Correlation MT1L expression levels with tumor stage, non-tumor tissue stage, radiation therapy, and residual tumor were analyzed. Further, MT1L expression was detected in PRAD cell lines by reverse transcription-quantitative polymerase chain reaction assay. Overexpression of MT1L was constructed and used for cell count kit-8, flow cytometric assay, transwell assay, and wound-healing assay.
Results: Survival analysis showed 15 Gleason-Score-related genes as prognostic biomarkers in PRAD. The high-frequency deletion of MT1L was verified in PRAD. Furthermore, MT1L expression was decreased in PRAD cell lines than RWPE-1 cells, and overexpression of MT1L repressed cell proliferation and migration, and induced apoptosis in PC-3 cells.
Conclusion: Gleason-Score-related MT1L may serve as a biomarker of poor prognostic biomarker in PRAD. In addition, MT1L plays a tumor suppressor in PRAD progression, which is beneficial for PRAD diagnosis and treatment research.
期刊介绍:
IJBM is an international, online only, peer-reviewed Journal, which publishes original research and critical reviews primarily focused on cancer biomarkers. IJBM targets advanced topics regarding the application of biomarkers in oncology and is dedicated to solid tumors in adult subjects. The clinical scenarios of interests are screening and early diagnosis of cancer, prognostic assessment, prediction of the response to and monitoring of treatment.